Screener
Nurix Therapeutics, Inc. NRIX Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.
- Filed
- Jul 9, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001549595-26-000040
| Line item | May 31,2026 | November 30,2025 |
|---|---|---|
| Total current assets | 456,481 | 606,819 |
| Operating lease right-of-use assets | 50,107 | 50,517 |
| Property and equipment, net | 20,007 | 22,490 |
| Restricted cash | 968 | 968 |
| Other assets | 7,977 | 7,341 |
| Total assets | $535,540 | $688,135 |
| Liabilities and stockholdersʼ equity | ||
| Current liabilities: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Nurix Therapeutics, Inc.'s restricted cash?
- Nurix Therapeutics, Inc. (NRIX) reported restricted cash of $968K in Q1 2026.
- How has Nurix Therapeutics, Inc.'s restricted cash changed year-over-year?
- Nurix Therapeutics, Inc.'s restricted cash increased by 7.4% year-over-year, from $901K to $968K.
- What is the long-term trend for Nurix Therapeutics, Inc.'s restricted cash?
- Over 5 years (2020 to 2025), Nurix Therapeutics, Inc.'s restricted cash has grown at a 41.6% compound annual growth rate (CAGR), from $170K to $968K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Nurix Therapeutics, Inc.'s restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude